The top-line results of the three pivotal imaging trials wereexpected during the first quarter of 2007, in addition to results of some additional Phase III lipid studies. Pfizer has, however, terminated ILLUMINATE and in fact, ended the development program for this compound, with participating patients being advised to stop taking the study medication immediately. According to Espicom's latest Pharmaceutical Companies Analysis report, Pfizer was investing approximately US$800 million in the development of T/A. Dr Philip Barter, Director of the Heart Research Institute in Australia and Chairman of the Steering Committee overseeing the ILLUMINATE study, clarified how surprised those blinded to the safety data were by the DSMB's information, stating that it was "totally unexpected and disappointing." At 1.40pm CET on 4th December, Pfizer's share price was EUR 18.00 in Frankfurt, down by 12.83 per cent from the previous day.